.webp)
What If Healthcare Started Before We Got Sick? How AYUN Is Bringing Longevity Medicine Into Everyday Life
From personalised diagnostics to measurable health improvements: Maximon portfolio company AYUN is demonstrating what the future of preventive healthcare could look like. Now, the Zurich-based longevity clinic is opening its next chapter through a public crowdinvesting round.
We invest in our education, careers, financial security and future. We plan years ahead, track our progress and make decisions based on the information available to us.
Yet when it comes to one of our most valuable assets, our health, we often take a surprisingly different approach: we wait.
We wait until something feels wrong. Until our energy declines, our sleep deteriorates or a routine examination reveals a problem that may have been developing for years.
Modern medicine has achieved extraordinary progress in diagnosing and treating disease. But what if the next major shift in healthcare is not simply about treating illness more effectively, but about understanding our health well enough to act earlier?
This is the idea behind longevity medicine. And at Maximon, we believe it has the potential to fundamentally change how people approach their health.
One of our portfolio companies, AYUN, is already turning that vision into a practical healthcare model.
From Reactive Healthcare to Proactive Health Management
For decades, healthcare has largely been organised around a familiar principle: identify a problem, diagnose it and treat it.
This approach remains essential. But advances in medical diagnostics, genetics and our understanding of human biology are creating new opportunities to complement it with something equally important: prevention.
Consider two people of the same age. Both feel healthy, exercise regularly and maintain relatively balanced lifestyles.
Yet beneath the surface, their biology may tell very different stories.
One might show early signs of insulin resistance. The other might have elevated cardiovascular risk markers, nutritional deficiencies or a genetic predisposition that makes certain preventive measures particularly relevant.
Neither may experience any noticeable symptoms.
And that is precisely the point.
Feeling healthy and understanding your health are not necessarily the same thing.
Today, a growing range of medically relevant biomarkers and diagnostic methods can help physicians identify risk factors, understand individual differences and uncover patterns that might otherwise remain unnoticed.
The real opportunity lies not in collecting as much data as possible, but in connecting the right information and translating it into meaningful decisions.
Because ultimately, the future of prevention is not about knowing more numbers. It is about knowing what to do with them.
Your Biology Is Unique and your Healthcare Should Reflect That.
The idea of personalised medicine is relatively simple: people are different, so their healthcare should not always follow the same blueprint.
Genetics, metabolism, lifestyle, medical history, environment and personal goals all contribute to an individual's health profile.
A nutrition strategy that works well for one person may not be appropriate for another. The same applies to exercise, recovery, sleep and certain medical interventions.
Understanding these differences can make preventive care more relevant and actionable.
This is where AYUN comes in.
Founded in 2022 and operating its longevity clinic in Zurich since 2024, AYUN combines comprehensive medical diagnostics with physician-led interpretation and personalized health strategies.
Its longevity check-ups assess more than 150 health-related data points, bringing together different dimensions of health rather than examining individual measurements in isolation.
Depending on the assessment, these insights can include metabolic and cardiovascular markers, physical performance, body composition and other relevant indicators. Genetic information may provide additional context where medically appropriate.
AYUN's medical team then translates the findings into a personalized plan, which may include lifestyle adjustments, nutrition, exercise, recovery strategies or medically guided interventions.
Importantly, the process does not end with a single check-up.
Follow-up assessments help evaluate how relevant health markers change over time, allowing recommendations to be refined based on measurable progress.
The approach is straightforward: establish a baseline, understand the individual, take targeted action and measure what changes.
It represents a different relationship with healthcare. One in which people are not simply patients when something goes wrong, but active participants in understanding and managing their long-term health.
Beyond the Vision: What AYUN Has Achieved So Far
Longevity is attracting increasing attention from scientists, entrepreneurs, investors and the wider public.
But as with any emerging field, an important question remains: can ambitious ideas translate into meaningful real-world outcomes and a sustainable business?
AYUN's development offers an encouraging early indication.
Since its launch, the company has:
Welcomed more than 1,500 clients to its preventive and longevity medicine offering.
Generated approximately CHF 2.7 million in cumulative revenue, demonstrating demand for its services.
Achieved a 60% retest rate, with clients returning to reassess their health and track progress.
Reported measurable health improvements in 7 out of 10 check-up clients who completed a retest, according to its crowdfunding campaign.
Attracted approximately 40% of new clients through personal recommendations, reflecting the importance of trust and client experience.
These figures tell an interesting story.
The revenue and client numbers demonstrate that people are willing to invest in understanding their health before illness necessarily becomes the motivating factor.
The retest rate suggests that a significant proportion see value in monitoring their progress rather than treating preventive diagnostics as a one-time experience.
And the reported improvements among returning clients suggest that personalised health strategies can be accompanied by measurable changes in assessed health indicators.
These are company-reported outcomes, not proof that AYUN's approach extends lifespan or prevents specific diseases. Nevertheless, they provide a tangible starting point for evaluating how preventive medicine can work in practice.
AYUN has also developed its proprietary Clinical Engine and AYUN Health Score, designed to bring health information, personalised recommendations and progress tracking together in a more accessible format.
This combination of medical expertise, technology and ongoing client relationships is central to the company's approach.
Making Longevity Part of Everyday Healthcare
For longevity medicine to create meaningful societal impact, it cannot remain a concept reserved for a small group of biohackers, elite athletes or technology enthusiasts.
It needs to become practical, understandable and increasingly accessible.
At Maximon, we see an important distinction between longevity as a trend and longevity as a long-term transformation of healthcare.
The first attracts attention. The second requires building real services, establishing medical standards, earning trust and demonstrating value over time.
AYUN is working on precisely that transition.
Beyond its longevity check-ups, the clinic has developed specialised offerings in women's health, including support across hormonal and reproductive health, menopause and other life stages.
This reflects a broader principle of personalised prevention: healthcare should adapt not only to an individual's biological profile, but also to their changing needs throughout life.
The same principle applies to how preventive healthcare could evolve beyond individual clinics.
Digital health platforms, employer health programmes and collaborations with healthcare partners may make ongoing health monitoring and personalised guidance more widely available.
There are, of course, important challenges. More testing does not automatically lead to better health outcomes, and preventive approaches must be supported by medical evidence, appropriate interpretation and responsible use of personal health data.
But the direction is becoming clearer.
The next evolution of healthcare could be one in which understanding and maintaining health becomes just as normal as seeking treatment when we are ill.
And businesses capable of translating that vision into trusted, medically responsible services have an important role to play.
From a Zurich Clinic to a Scalable Healthcare Model
AYUN's first clinic in Zurich has provided a foundation for validating its concept, building its medical team and learning directly from client needs.
The company's next challenge is to build on that foundation.
Its growth strategy focuses on three connected areas:
Expanding its Zurich operations. Increasing capacity and strengthening the medical and operational infrastructure to serve a growing client base.
Developing its technology platform. Further connecting health data, medical interpretation, personalised recommendations and long-term progress tracking to support a more scalable model.
Building new growth channels. Developing corporate health partnerships, expanding B2B offerings and preparing for additional locations and broader market reach.
The ambition is not simply to replicate a clinic.
It is to develop a healthcare model in which technology supports medical professionals, data informs individual decisions and long-term preventive care becomes easier to integrate into everyday life.
For Maximon, this is exactly the kind of opportunity that makes the longevity sector compelling: combining scientific progress with entrepreneurship to create services that can have a measurable impact on people's lives.
AYUN Opens Its Next Growth Chapter to Private Investors
Until now, AYUN's development has been supported by experienced investors, including longevity company builder Maximon and entrepreneurs and investors such as Dr. Tobias Reichmuth and Marc P. Bernegger.
Now, the company is taking another step.
From 15 October 2026, AYUN is opening its public crowdinvesting round through the Swiss investment platform CONDA, giving private investors the opportunity to participate in its next phase of development.
The campaign aims to raise growth capital to support the expansion of the Zurich clinic, further technology development and the company's broader growth strategy.
Beyond the investment itself, the crowdinvesting model introduces another interesting dimension: people who believe in proactive healthcare can become financially involved in building the businesses bringing it into practice.
Depending on the investment amount, participants may also receive additional AYUN benefits, including investor discounts and credits towards selected check-ups and treatments.
The Bigger Opportunity: Making Prevention the New Normal
The most interesting aspect of AYUN's story may not be its first clinic, its technology or even its next phase of growth.
It is the broader change in mindset that the company represents.
Imagine a future in which having a clear understanding of your metabolic health, cardiovascular risk factors and physical performance is a routine part of looking after yourself.
Where medical recommendations reflect not only general population guidelines, but also your personal history, relevant genetic information, current health status and individual goals.
Where progress is monitored over time, and preventive healthcare becomes an ongoing relationship rather than an occasional appointment.
Not every disease can be prevented, and longevity medicine is not a promise of indefinite youth. But better information, medical expertise and evidence-based action can help people make more informed decisions about their health.
That is a future worth working towards.
At Maximon, our conviction is that longevity will increasingly become part of mainstream healthcare, not because people want to live forever, but because they want to remain healthy, active and independent for as long as possible.
AYUN is one example of how that future is already beginning to take shape.
And with its upcoming crowdinvesting round, more people now have the opportunity to participate in the company's next chapter.
Interested in learning more about AYUN's business model and plans? The company's CEO, Ildikó Sirman, is available to discuss its vision and next steps.
Investment disclaimer: Investing in AYUN involves risks, including the potential loss of the entire invested capital. Historical operating results and reported health outcomes do not guarantee future performance. Further information about the investment structure, terms and associated risks is available in the official CONDA campaign documentation.
